Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13816297 | 0.90 | PTGDR2 (0.68) | PTGDR2PTGDR | |
| SCHEMBL13816296 | 0.89 | PTGDR2 (0.60) | PTGDR2PTGDRALDH1A1KDM4ENPSR1 | |
| SCHEMBL14646991 | 0.82 | PTGDR2 (0.71) | PTGDR2PTGDR | |
| SCHEMBL4518983 | 0.79 | PTGDR2 (0.59) | PTGDR2PTGDRALDH1A1KDM4ENPSR1 | |
| SCHEMBL4509561 | 0.79 | PTGDR2 (0.71) | PTGDR2PTGDRALDH1A1NPSR1MAPT | |
| SCHEMBL17347396 | 0.78 | ALDH1A1 (0.58) | PTGDR2ALDH1A1KDM4ENPSR1MAPT | |
| SCHEMBL13816298 | 0.77 | PTGDR2 (0.59) | PTGDR2PTGDRALDH1A1CCR2 | |
| SCHEMBL4505489 | 0.75 | PTGDR2 (0.68) | PTGDR2PTGDRALDH1A1KDM4ECCR2 | |
| SCHEMBL14311391 | 0.73 | CYP2C9 (0.60) | PTGDR2CCR2 | |
| SCHEMBL17347402 | 0.72 | KDM1A (0.61) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | PTGDR2 200/4885PTGDR 185/4885ALDH1A1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.